Dual GIP and GLP-1 receptor agonism reducing energy intake.
What was measuredSURMOUNT-1 (n≈2,539): mean weight loss ≈20.9% at 72 weeks on the highest dose, the largest reported for an approved drug.
Also known as GIP/GLP-1 dual agonist · developed by Eli Lilly
Licensed by at least one major regulator for a specific indication, on the strength of completed phase 3 trials. Approval is for that indication in that population — it is not a general endorsement of the compound.
A single molecule that activates two incretin receptors — GIP and GLP-1 — built on a GIP backbone with substitutions that resist degradation and a fatty acid chain for weekly dosing.
Dual agonist at GIP and GLP-1 receptors. The contribution of GIP agonism is still debated: it improves insulin sensitivity and may reduce the nausea burden relative to GLP-1 alone, but the mechanism behind the larger weight effect is not settled.
SURMOUNT-1 reported mean weight loss around 21% at 72 weeks at the highest dose. SURMOUNT-5, a head-to-head against semaglutide, found greater reduction with tirzepatide (approximately 20% versus 14%).
The SURPASS programme showed HbA1c reductions exceeding comparators including insulin and semaglutide in type 2 diabetes.
SURMOUNT-OSA reported reductions in apnoea-hypopnoea index, leading to an additional licensed indication.
This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.
Licensed for type 2 diabetes (Mounjaro) and weight management and OSA (Zepbound). Prescription-only in the UK, EU and US.
The sites below are where Tirzepatide is understood to act, paired with what was actually measured there and in whom. A site on this diagram means a compound acts there — not that a benefit is established.
Drag to turn · tap an organ
Dual GIP and GLP-1 receptor agonism reducing energy intake.
What was measuredSURMOUNT-1 (n≈2,539): mean weight loss ≈20.9% at 72 weeks on the highest dose, the largest reported for an approved drug.
Increases glucose-dependent insulin secretion.
What was measuredSURPASS programme: HbA1c reductions exceeding semaglutide 1mg in a head-to-head trial in type 2 diabetes.
GIP receptor agonism is proposed to improve insulin sensitivity in adipose tissue.
What was measuredThe contribution of GIP to the weight effect is debated and not settled. This arm of the mechanism is proposed, not demonstrated.
Reduces obstructive sleep apnoea severity.
What was measuredSURMOUNT-OSA: clinically meaningful reduction in apnoea-hypopnoea index in adults with obesity and moderate-to-severe OSA.
A long-acting analogue of GLP-1, a hormone the gut releases after eating. Structural changes — an Aib substitution that …
An investigational agonist at three receptors — GIP, GLP-1 and glucagon. The glucagon component is what distinguishes it…
A fragment of the C-terminus of human growth hormone, developed specifically as a weight-loss drug on the theory that th…
This site publishes summaries of published research. It is not medical advice, and Genexis Health does not sell or supply any compound described here. Please confirm each statement below to continue.
We ask everyone to confirm they understand this site is information rather than medical advice before reading it. Because you have not confirmed those statements, you cannot continue.
If you are looking for health advice or treatment, please speak to a licensed healthcare professional. Nothing on this site is a substitute for that.